CG
IGMS

Cutler Group’s IGM Biosciences IGMS Stock Holding History

Cutler Group’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400
Closed -$3K – 3929
2023
Q3 		$3K Buy
+400
New +$3.39K ﹤0.01% 3100
2023
Q1 		– Sell
-100
Closed -$1K – 4228
2022
Q4 		$1K Sell
100
-10
-9% -$200 ﹤0.01% 4043
2022
Q3 		$2K Buy
+110
New +$2.22K ﹤0.01% 4215
2022
Q2 		– Sell
-700
Closed -$12.5K – 5276
2022
Q1 		$18K Buy
+700
New +$13K ﹤0.01% 3144

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cutler Group's IGMS Position: Q4 2023 in Review

Cutler Group sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 400 shares — an estimated $3K sold.

Cutler Group first reported a position in IGMS in Q1 2022 and held it in 4 quarters. The position peaked at $18K in Q1 2022. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

  • Cutler Group reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 400 IGM Biosciences shares in Q4 2023, an estimated $3K.
  • Cutler Group first reported a position in IGM Biosciences in Q1 2022 and held it in 4 quarters.
  • Cutler Group's IGM Biosciences position peaked at $18K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.